tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Alan Carr, 104 are a BUY (93.69%), 7 are a HOLD (6.31%).
Analyst Alan Carr, carries an average stock price target met ratio of 63.11% that have a potential upside of 30.43% achieved within 429 days. Previously, Alan Carr worked at NEEDHAM.
Alan Carr’s has documented 211 price targets and ratings displayed on 30 stocks. The coverage was on Healthcare, Industrials sectors.
Most recent stock forecast was given on PLRX, Pliant Therapeutics at 09-Feb-2025.
Analyst best performing recommendations are on GNCA (GENOCEA BIOSCIENCES).
The best stock recommendation documented was for GNCA (GENOCEA BIOSCIENCES) at 3/5/2014. The price target of $176 was fulfilled within 2 days with a profit of $45.04 (34.39%) receiving and performance score of 171.96.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Feb-2022
$82
$32.75 (66.50%)
$82
1 months 20 days ago
(31-Aug-2026)
8/30 (26.67%)
$25.02 (43.91%)
214
Buy Since 12-Nov-2019
$80
$30.75 (62.44%)
$80
1 months 20 days ago
(31-Aug-2026)
13/30 (43.33%)
$23.02 (40.40%)
159
Buy Since 18-Apr-2024
$88
$38.75 (78.68%)
$82
2 months 17 days ago
(04-Aug-2026)
11/21 (52.38%)
$34.93 (65.82%)
145
Buy Since 03-Feb-2025
$80
$30.75 (62.44%)
$80
3 months 13 days ago
(08-Jul-2026)
5/9 (55.56%)
$20.8 (35.14%)
82
Hold Since 11-Jun-2026
$60
$5.08 (9.25%)
$32
4 months 10 days ago
(11-Jun-2026)
8/9 (88.89%)
$9.77 (19.45%)
254
